Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Fellow in Hematology-Oncology, Medicine, Duke University 1992 - 1995
  • Medical Resident, Medicine, Duke University 1989 - 1992
  • M.D., Baylor University 1989
• 

  Previous Appointments & Affiliations

  • Professor of Medicine, Medicine, Medical Oncology, Medicine 2017 - 2021
  • Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 2013 - 2017
  • Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 2010 - 2013
  • Assistant Professor of Medicine, Medicine, Medical Oncology, Medicine 2004 - 2010
  • Associate in the Department of Medicine, Medicine, Medical Oncology, Medicine 1997 - 2004
  • Instructor, Temporary in the Medicine, Medicine, Medical Oncology, Medicine 1997
• Research
• 

  Selected Grants

  • TBCRC 041 Randomized Phase II Trial to Evaluate Alisertib Alone or Combined with Fulvestrant in Women with Advanced, Hormone-Receptor Positive (HR+) Breast Cancer awarded by Mayo Clinic 2019 - 2023
  • Kastan Gray Foundation Project awarded by Gray Foundation 2017 - 2023
  • Postdoctoral Training in Genomic Medicine Research awarded by National Institutes of Health 2017 - 2023
  • TBCRC AURORA US:RETROSPECTIVE TISSUE COLLECTION awarded by Johns Hopkins University 2017 - 2023
  • A phase I/Ib, open label study of LSZ102 single agent and LSZ102 in combination with eitherLEE011 (LSZ102 + LEE011) or BYL719 (LSZ102 + BYL719) in patients with advanced or metastatic ER+ breast cancer who have progressed after endocrine therapy. awarded by Novartis Pharmaceuticals Corporation 2016 - 2022
  • TBCRC48 A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes "Olaparib Expanded" awarded by Johns Hopkins University 2018 - 2022
  • Targeting tumor-specific apoptosis regulation in advanced ER+ breast cancer awarded by Department of Defense 2019 - 2022
  • Translational Breast Cancer Research Consortium 2020 Infrastructure (BCRF) awarded by Johns Hopkins University 2020 - 2022
  • Translational Breast Cancer Research Consortium 2020 Infrastructure - SGK awarded by Johns Hopkins University 2020 - 2022
  • A RANDOMIZED PHASE II STUDY OF PREOPERATIVE CISPLATIN VS PACLITAXEL IN PATIENTS WITH TRIPLE NEGATIVE BREAST CANCER WITHOUT GERMLINE BRCA MUTATIONS: EVALUATING THE HOMOLOGOUS RECOMBINATION DEFICIENCY (HRB) BIOMARKER awarded by Dana-Farber Cancer Institute 2014 - 2022
  • Targeting Dormant Breast Cancer Micrometastases to Prevent Disease Relapse awarded by American Cancer Society, Inc. 2019 - 2022
  • A randomized phase II study of adjuvant Trastuzumab emtansine (T-DM1) vs Paclitaxel in combination with Trastuzumab for stage I HER2-positive breast cancer (ATEMPT Trial) awarded by Dana-Farber Cancer Institute 2014 - 2021
  • Translational Breast Cancer Research Consortium 2019 Infrastructure (BCRF) awarded by Johns Hopkins University 2019 - 2021
  • Translational Breast Cancer Research Consortium 2019 Infrastructure - SGK awarded by Johns Hopkins University 2019 - 2021
  • Deep learning for prognostication in breast cancer awarded by North Carolina Biotechnology Center 2018 - 2021
  • Translational Breast Cancer Research Consortium 2018 Infrastructure (BCRF) awarded by Johns Hopkins University 2018 - 2020
  • Translational Breast Cancer Research Consortium 2018 Infrastructure - SGK awarded by Johns Hopkins University 2018 - 2020
  • Can contrast dynamics in breast MRI predict genomic intra-tumor heterogeneity awarded by Bracco Diagnostics, Inc. 2016 - 2020
  • Targeting precursor neural (N)-cadherin to eliminate chemotherapy-resistant triple-negative breast tumor cells awarded by Department of Defense 2017 - 2020
  • A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients with Advanced Breast Cancer. awarded by Innocrin Pharmaceutical, Inc. 2016 - 2019
  • Translational Breast Cancer Research Consortium-2017 Komen Foundation SGK awarded by Johns Hopkins University 2018 - 2019
  • RANDOMIZED PHASE II TRIAL OF NEOADJUVANT CISPLATIN VS. DOXORUBICIN/CYCLOPHOSPHAMIDE (¿AC¿) IN WOMEN WITH NEWLY DIAGNOSED BREAST CANCER AND GERMLINE BRCA MUTATIONS awarded by Johns Hopkins University 2015 - 2019
  • TBCRC 031 INFORM (Beth Israel) awarded by Beth Israel Deaconess Medical Center 2015 - 2019
  • A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC awarded by Merck Sharp & Dohme 2017 - 2018
  • A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (CDX011-04) awarded by Celldex Therapeutics, Inc. 2014 - 2018
  • A PHASE II RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED STUDY OF LETROZOLE WITH OR WITHOUT BYL719 OR BUPARLISIB, FOR THE NEOADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE HER2-NEGATIVE BREAST CANCER awarded by Novartis Pharmaceuticals Corporation 2013 - 2017
  • Commericialization of a computational imaging-based biomarker for prognostication in breast cancer awarded by North Carolina Biotechnology Center 2016 - 2017
  • Targeting nuclear FGF receptor to improve chemotherapy response in triple-negative breast cancer awarded by Department of Defense 2013 - 2016
  • Clinical Oncology Research Career Development Program awarded by National Institutes of Health 2009 - 2015
  • Randomized Trial of Optimal Type of Aerobic Training in Breast Cancer awarded by National Institutes of Health 2010 - 2014
  • Programs in Clinical Effectiveness of Cancer Pharmacogenomics awarded by National Institutes of Health 2009 - 2012
  • Markers of short term breast cancer risk in FNA awarded by National Institutes of Health 1995 - 2008
  • Phase II trial of Cetuximab & Carboplatin in Basal-like Breast Cancer awarded by National Institutes of Health 1995 - 2008
  • Carolina and Georgia Genetics Network Center awarded by National Institutes of Health 1998 - 2008
  • Phase II Trial of Estradiol Therapy for Advanced Breast Cancer awarded by National Institutes of Health 2003 - 2005
  • Carolina and Georgia Genetics Network Center awarded by National Institutes of Health 1998 - 2004
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Garcia-Recio, Susana, Toshinori Hinoue, Gregory L. Wheeler, Benjamin J. Kelly, Ana C. Garrido-Castro, Tomas Pascual, Aguirre A. De Cubas, et al. “Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis.” Nat Cancer 4, no. 1 (January 2023): 128–47. https://doi.org/10.1038/s43018-022-00491-x.
       Full Text  Link to Item
    • Smith, Claire E. P., Paul K. Marcom, Zahi Mitri, and Naomi Y. Ko. “Predictors of long-term durable response in de novo HER2-positive metastatic breast cancer and the real-world treatment experience at two institutions.” Breast Cancer Res Treat 196, no. 1 (November 2022): 215–20. https://doi.org/10.1007/s10549-022-06718-w.
       Full Text  Link to Item
    • Ma, Cynthia X., Jingqin Luo, Rachel A. Freedman, Timothy J. Pluard, Julie R. Nangia, Janice Lu, Frances Valdez-Albini, et al. “The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer.” Clin Cancer Res 28, no. 7 (April 1, 2022): 1258–67. https://doi.org/10.1158/1078-0432.CCR-21-3418.
       Full Text  Link to Item
    • Robinson, Timothy J., Lauren E. Wilson, P Kelly Marcom, Melissa Troester, Charles F. Lynch, Brenda Y. Hernandez, Edgardo Parrilla, Heather Ann Brauer, and Michaela A. Dinan. “Analysis of Sociodemographic, Clinical, and Genomic Factors Associated With Breast Cancer Mortality in the Linked Surveillance, Epidemiology, and End Results and Medicare Database.” Jama Network Open 4, no. 10 (October 2021): e2131020. https://doi.org/10.1001/jamanetworkopen.2021.31020.
       Full Text
    • Paoletti, Costanza, Meredith M. Regan, Samuel M. Niman, Emily M. Dolce, Elizabeth P. Darga, Minetta C. Liu, P Kelly Marcom, et al. “Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients.” Npj Breast Cancer 7, no. 1 (June 11, 2021): 77. https://doi.org/10.1038/s41523-021-00281-1.
       Full Text  Link to Item
    • Fayanju, Oluwadamilola M., Yi Ren, Ilona Stashko, Steve Power, Madeline J. Thornton, P Kelly Marcom, Terry Hyslop, and E Shelley Hwang. “Patient-reported causes of distress predict disparities in time to evaluation and time to treatment after breast cancer diagnosis.” Cancer 127, no. 5 (March 1, 2021): 757–68. https://doi.org/10.1002/cncr.33310.
       Full Text  Link to Item
    • Tung, Nadine M., Mark E. Robson, Steffen Ventz, Cesar A. Santa-Maria, Rita Nanda, Paul K. Marcom, Payal D. Shah, et al. “TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.” J Clin Oncol 38, no. 36 (December 20, 2020): 4274–82. https://doi.org/10.1200/JCO.20.02151.
       Full Text  Link to Item
    • Mayer, E. L., V. Abramson, R. Jankowitz, C. Falkson, P. K. Marcom, T. Traina, L. Carey, et al. “TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.” Ann Oncol 31, no. 11 (November 2020): 1518–25. https://doi.org/10.1016/j.annonc.2020.08.2064.
       Full Text  Link to Item
    • Nichols, Brandon S., Erika Chelales, Roujia Wang, Amanda Schulman, Jennifer Gallagher, Rachel A. Greenup, Joseph Geradts, et al. “Quantitative assessment of distant recurrence risk in early stage breast cancer using a nonlinear combination of pathological, clinical and imaging variables.” J Biophotonics 13, no. 10 (October 2020): e201960235. https://doi.org/10.1002/jbio.201960235.
       Full Text  Link to Item
    • Tung, Nadine, Banu Arun, Michele R. Hacker, Erin Hofstatter, Deborah L. Toppmeyer, Steven J. Isakoff, Virginia Borges, et al. “TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial).” J Clin Oncol 38, no. 14 (May 10, 2020): 1539–48. https://doi.org/10.1200/JCO.19.03292.
       Full Text  Link to Item
    • Gradishar, William J., Benjamin O. Anderson, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H. Allison, Sarah L. Blair, et al. “Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : Jnccn 18, no. 4 (April 2020): 452–78. https://doi.org/10.6004/jnccn.2020.0016.
       Full Text
    • Kikuchi, Robin, Gloria Broadwater, Rebecca Shelby, Jessica Robertson, Leah L. Zullig, Bailey Maloney, Claudia Meyer, et al. “Detecting geriatric needs in older patients with breast cancer through use of a brief geriatric screening tool.” J Geriatr Oncol 10, no. 6 (November 2019): 968–72. https://doi.org/10.1016/j.jgo.2019.04.010.
       Full Text  Link to Item
    • Strickler, John H., Christel N. Rushing, Donna Niedzwiecki, Abigail McLeod, Ivy Altomare, Hope E. Uronis, S David Hsu, et al. “A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer.” Bmc Cancer 19, no. 1 (November 1, 2019): 1032. https://doi.org/10.1186/s12885-019-6234-8.
       Full Text  Link to Item
    • Fayanju, Oluwadamilola M., Karine Yenokyan, Yi Ren, Benjamin A. Goldstein, Ilona Stashko, Steve Power, Madeline J. Thornton, P Kelly Marcom, and E Shelley Hwang. “The effect of treatment on patient-reported distress after breast cancer diagnosis.” Cancer 125, no. 17 (September 1, 2019): 3040–49. https://doi.org/10.1002/cncr.32174.
       Full Text  Link to Item
    • Dorfman, Caroline S., Sarah S. Arthur, Gretchen G. Kimmick, Kelly W. Westbrook, Paul Kelly Marcom, Cheyenne Corbett, Sara N. Edmond, and Rebecca A. Shelby. “Partner status moderates the relationships between sexual problems and self-efficacy for managing sexual problems and psychosocial quality-of-life for postmenopausal breast cancer survivors taking adjuvant endocrine therapy.” Menopause 26, no. 8 (August 2019): 823–32. https://doi.org/10.1097/GME.0000000000001337.
       Full Text  Link to Item
    • Tolaney, Sara M., Hao Guo, Sonia Pernas, William T. Barry, Deborah A. Dillon, Lauren Ritterhouse, Bryan P. Schneider, et al. “Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.” J Clin Oncol 37, no. 22 (August 1, 2019): 1868–75. https://doi.org/10.1200/JCO.19.00066.
       Full Text  Link to Item
    • Bellon, Jennifer R., Hao Guo, William T. Barry, Chau T. Dang, Denise A. Yardley, Beverly Moy, P Kelly Marcom, et al. “Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial).” Breast Cancer Res Treat 176, no. 2 (July 2019): 303–10. https://doi.org/10.1007/s10549-019-05238-4.
       Full Text  Link to Item
    • Mazurowski, Maciej A., Ashirbani Saha, Michael R. Harowicz, Elizabeth Hope Cain, Jeffrey R. Marks, and P Kelly Marcom. “Association of distant recurrence-free survival with algorithmically extracted MRI characteristics in breast cancer.” J Magn Reson Imaging 49, no. 7 (June 2019): e231–40. https://doi.org/10.1002/jmri.26648.
       Full Text  Link to Item
    • Crosby, Erika J., William Gwin, Kimberly Blackwell, Paul K. Marcom, Serena Chang, Holden T. Maecker, Gloria Broadwater, et al. “Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study.” Clin Cancer Res 25, no. 9 (May 1, 2019): 2725–36. https://doi.org/10.1158/1078-0432.CCR-18-3102.
       Full Text  Open Access Copy  Link to Item
    • Barroso-Sousa, R., W. T. Barry, H. Guo, D. Dillon, Y. B. Tan, K. Fuhrman, W. Osmani, et al. “The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial.” Ann Oncol 30, no. 4 (April 2019): 575–81. https://doi.org/10.1093/annonc/mdz047.
       Full Text  Link to Item
    • Sitlinger, Andrea, Rebecca A. Shelby, Alyssa N. Van Denburg, Heidi White, Sarah N. Edmond, Paul K. Marcom, Hayden B. Bosworth, Francis J. Keefe, and Gretchen G. Kimmick. “Higher symptom burden is associated with lower function in women taking adjuvant endocrine therapy for breast cancer.” J Geriatr Oncol 10, no. 2 (March 2019): 317–21. https://doi.org/10.1016/j.jgo.2018.11.008.
       Full Text  Link to Item
    • Goetz, Matthew P., William J. Gradishar, Benjamin O. Anderson, Jame Abraham, Rebecca Aft, Kimberly H. Allison, Sarah L. Blair, et al. “NCCN Guidelines Insights: Breast Cancer, Version 3.2018.” J Natl Compr Canc Netw 17, no. 2 (February 2019): 118–26. https://doi.org/10.6004/jnccn.2019.0009.
       Full Text  Link to Item
    • Cain, Elizabeth Hope, Ashirbani Saha, Michael R. Harowicz, Jeffrey R. Marks, P Kelly Marcom, and Maciej A. Mazurowski. “Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set.” Breast Cancer Res Treat 173, no. 2 (January 2019): 455–63. https://doi.org/10.1007/s10549-018-4990-9.
       Full Text  Link to Item
    • Devi, Gayathri R., Holly Hough, Nadine Barrett, Massimo Cristofanilli, Beth Overmoyer, Neil Spector, Naoto T. Ueno, et al. “Perspectives on Inflammatory Breast Cancer (IBC) Research, Clinical Management and Community Engagement from the Duke IBC Consortium.” J Cancer 10, no. 15 (2019): 3344–51. https://doi.org/10.7150/jca.31176.
       Full Text  Open Access Copy  Link to Item
    • Saha, Ashirbani, Michael R. Harowicz, Elizabeth Hope Cain, Allison H. Hall, Eun-Sil Shelley Hwang, Jeffrey R. Marks, Paul Kelly Marcom, and Maciej A. Mazurowski. “Intra-tumor molecular heterogeneity in breast cancer: definitions of measures and association with distant recurrence-free survival.” Breast Cancer Res Treat 172, no. 1 (November 2018): 123–32. https://doi.org/10.1007/s10549-018-4879-7.
       Full Text  Link to Item
    • Force, Jeremy, Lynn J. Howie, Sara E. Abbott, Rex Bentley, P Kelly Marcom, Gretchen Kimmick, Kelly Westbrook, et al. “Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype.” Clin Breast Cancer 18, no. 5 (October 2018): 410–17. https://doi.org/10.1016/j.clbc.2018.02.010.
       Full Text  Link to Item
    • McRee, Autumn J., Paul K. Marcom, Dominic T. Moore, William C. Zamboni, Zachary A. Kornblum, Zhiyuan Hu, Rachel Phipps, et al. “A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer.” Clin Breast Cancer 18, no. 4 (August 2018): 289–97. https://doi.org/10.1016/j.clbc.2017.10.014.
       Full Text  Link to Item
    • Gradishar, William J., Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, et al. “Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 16, no. 3 (March 2018): 310–20. https://doi.org/10.6004/jnccn.2018.0012.
       Full Text  Link to Item
    • Han, H. S., V. Diéras, M. Robson, M. Palácová, P. K. Marcom, A. Jager, I. Bondarenko, et al. “Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.” Annals of Oncology : Official Journal of the European Society for Medical Oncology 29, no. 1 (January 2018): 154–61. https://doi.org/10.1093/annonc/mdx505.
       Full Text
    • Harowicz, Michael R., Ashirbani Saha, Lars J. Grimm, P Kelly Marcom, Jeffrey R. Marks, E Shelley Hwang, and Maciej A. Mazurowski. “Can algorithmically assessed MRI features predict which patients with a preoperative diagnosis of ductal carcinoma in situ are upstaged to invasive breast cancer?” J Magn Reson Imaging 46, no. 5 (November 2017): 1332–40. https://doi.org/10.1002/jmri.25655.
       Full Text  Link to Item
    • Gamble, Charlotte, Laura J. Havrilesky, Evan R. Myers, Junzo P. Chino, Scott Hollenbeck, Jennifer K. Plichta, P. Kelly Marcom, E. Shelley Hwang, Noah D. Kauff, and Rachel A. Greenup. “Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer.” Ann Surg Oncol 24, no. 11 (October 2017): 3116–23. https://doi.org/10.1245/s10434-017-5995-z.
       Full Text  Link to Item
    • Gradishar, William J., Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, et al. “NCCN Guidelines Insights: Breast Cancer, Version 1.2017.” Journal of the National Comprehensive Cancer Network : Jnccn 15, no. 4 (April 2017): 433–51. https://doi.org/10.6004/jnccn.2017.0044.
       Full Text
    • Buchanan, Adam H., Corrine I. Voils, Joellen M. Schildkraut, Catherine Fine, Nora K. Horick, P Kelly Marcom, Kristi Wiggins, and Celette Sugg Skinner. “Adherence to Recommended Risk Management among Unaffected Women with a BRCA Mutation.” J Genet Couns 26, no. 1 (February 2017): 79–92. https://doi.org/10.1007/s10897-016-9981-6.
       Full Text  Link to Item
    • Harowicz, Michael R., Timothy J. Robinson, Michaela A. Dinan, Ashirbani Saha, Jeffrey R. Marks, P Kelly Marcom, and Maciej A. Mazurowski. “Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset.” Breast Cancer Res Treat 162, no. 1 (February 2017): 1–10. https://doi.org/10.1007/s10549-016-4093-4.
       Full Text  Link to Item
    • Nelson, Erik R., Shenduo Li, Margaret Kennedy, Sturgis Payne, Kelly Kilibarda, Jeffrey Groth, Michelle Bowie, et al. “Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface.” Oncotarget 7, no. 51 (December 20, 2016): 84030–42. https://doi.org/10.18632/oncotarget.12767.
       Full Text  Link to Item
    • Kamal, Arif, Tian Zhang, Steve Power, and P Kelly Marcom. “Is Advanced Imaging in Early-Stage Breast Cancer Ever Warranted? Reconciling Clinical Judgment With Common Quality Measures.” J Natl Compr Canc Netw 14, no. 8 (August 2016): 993–98. https://doi.org/10.6004/jnccn.2016.0106.
       Full Text  Link to Item
    • Gradishar, William J., Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, et al. “Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 14, no. 3 (March 2016): 324–54. https://doi.org/10.6004/jnccn.2016.0037.
       Full Text  Link to Item
    • Daly, Mary B., Robert Pilarski, Jennifer E. Axilbund, Michael Berry, Saundra S. Buys, Beth Crawford, Meagan Farmer, et al. “Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015.” J Natl Compr Canc Netw 14, no. 2 (February 2016): 153–62. https://doi.org/10.6004/jnccn.2016.0018.
       Full Text  Link to Item
    • Buchanan, Adam H., Santanu K. Datta, Celette Sugg Skinner, Gail P. Hollowell, Henry F. Beresford, Thomas Freeland, Benjamin Rogers, John Boling, P Kelly Marcom, and Martha B. Adams. “Randomized Trial of Telegenetics vs. In-Person Cancer Genetic Counseling: Cost, Patient Satisfaction and Attendance.” J Genet Couns 24, no. 6 (December 2015): 961–70. https://doi.org/10.1007/s10897-015-9836-6.
       Full Text  Link to Item
    • Gradishar, William J., Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, et al. “NCCN Guidelines Insights Breast Cancer, Version 1.2016.” J Natl Compr Canc Netw 13, no. 12 (December 2015): 1475–85. https://doi.org/10.6004/jnccn.2015.0176.
       Full Text  Link to Item
    • Mazurowski, Maciej A., Lars J. Grimm, Jing Zhang, P Kelly Marcom, Sora C. Yoon, Connie Kim, Sujata V. Ghate, and Karen S. Johnson. “Recurrence-free survival in breast cancer is associated with MRI tumor enhancement dynamics quantified using computer algorithms.” Eur J Radiol 84, no. 11 (November 2015): 2117–22. https://doi.org/10.1016/j.ejrad.2015.07.012.
       Full Text  Link to Item
    • Kimmick, Gretchen, Sara N. Edmond, Hayden B. Bosworth, Jeffrey Peppercorn, Paul K. Marcom, Kimberly Blackwell, Francis J. Keefe, and Rebecca A. Shelby. “Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy.” Breast 24, no. 5 (October 2015): 630–36. https://doi.org/10.1016/j.breast.2015.06.010.
       Full Text  Link to Item
    • Sutton, Linda M., Joseph Geradts, Erika P. Hamilton, Kathleen A. Havlin, Gretchen G. Kimmick, P Kelly Marcom, Neil L. Spector, et al. “CHAMBER: A Regional Performance Improvement CME Initiative for Breast Cancer Health Care Providers.” J Natl Compr Canc Netw 13, no. 8 (August 2015): 1005–11. https://doi.org/10.6004/jnccn.2015.0121.
       Full Text  Link to Item
    • Li, Shenduo, Sturgis Payne, Fang Wang, Peter Claus, Zuowei Su, Jeffrey Groth, Joseph Geradts, et al. “Nuclear basic fibroblast growth factor regulates triple-negative breast cancer chemo-resistance.” Breast Cancer Res 17, no. 1 (July 4, 2015): 91. https://doi.org/10.1186/s13058-015-0590-3.
       Full Text  Link to Item
    • Silva, Grace O., Xiaping He, Joel S. Parker, Michael L. Gatza, Lisa A. Carey, Jack P. Hou, Stacy L. Moulder, et al. “Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer.” Breast Cancer Res Treat 152, no. 2 (July 2015): 347–56. https://doi.org/10.1007/s10549-015-3476-2.
       Full Text  Link to Item
    • Bossuyt, V., E. Provenzano, W. F. Symmans, J. C. Boughey, C. Coles, G. Curigliano, J. M. Dixon, et al. “Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.” Ann Oncol 26, no. 7 (July 2015): 1280–91. https://doi.org/10.1093/annonc/mdv161.
       Full Text  Link to Item
    • Ruddy, Kathryn J., Hao Guo, William Barry, Chau T. Dang, Denise A. Yardley, Beverly Moy, P Kelly Marcom, et al. “Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial).” Breast Cancer Res Treat 151, no. 3 (June 2015): 589–96. https://doi.org/10.1007/s10549-015-3426-z.
       Full Text  Link to Item
    • Yadav, Budhi S., S. C. Sharma, Tyler P. Robin, Sharon Sams, Anothony D. Elias, Virginia Kaklamani, P. Kelly Marcom, Sara Schaefer, and Gloria J. Morris. “Synchronous primary carcinoma of breast and ovary versus ovarian metastases.” Semin Oncol 42, no. 2 (April 2015): e13–24. https://doi.org/10.1053/j.seminoncol.2014.12.020.
       Full Text  Link to Item
    • Gradishar, William J., Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, et al. “Breast Cancer Version 2.2015.” J Natl Compr Canc Netw 13, no. 4 (April 2015): 448–75. https://doi.org/10.6004/jnccn.2015.0060.
       Full Text  Link to Item
    • Magbanua, Mark Jesus M., Lisa A. Carey, Amy DeLuca, Jimmy Hwang, Janet H. Scott, Mothaffar F. Rimawi, Erica L. Mayer, et al. “Circulating tumor cell analysis in metastatic triple-negative breast cancers.” Clin Cancer Res 21, no. 5 (March 1, 2015): 1098–1105. https://doi.org/10.1158/1078-0432.CCR-14-1948.
       Full Text  Link to Item
    • Grimm, Lars J., Karen S. Johnson, P Kelly Marcom, Jay A. Baker, and Mary S. Soo. “Can breast cancer molecular subtype help to select patients for preoperative MR imaging?” Radiology 274, no. 2 (February 2015): 352–58. https://doi.org/10.1148/radiol.14140594.
       Full Text  Link to Item
    • Tolaney, Sara M., William T. Barry, Chau T. Dang, Denise A. Yardley, Beverly Moy, P Kelly Marcom, Kathy S. Albain, et al. “Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.” N Engl J Med 372, no. 2 (January 8, 2015): 134–41. https://doi.org/10.1056/NEJMoa1406281.
       Full Text  Link to Item
    • Barry, William T., Charles M. Perou, P Kelly Marcom, Lisa A. Carey, and Joseph G. Ibrahim. “The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies.” J Biopharm Stat 25, no. 1 (2015): 66–88. https://doi.org/10.1080/10543406.2014.919933.
       Full Text  Link to Item
    • Li, S., S. Payne, F. Wang, P. Claus, Z. Su, J. Groth, J. Geradts, et al. “Nuclear basic fibroblast growth factor regulates triple-negative breast cancer chemo-resistance.” Breast Cancer Research, 2015. https://doi.org/10.1186/s13058-015-0590-3.
       Full Text
    • Shelby, Rebecca A., Sara N. Edmond, Anava A. Wren, Francis J. Keefe, Jeffrey M. Peppercorn, Paul K. Marcom, Kimberly L. Blackwell, and Gretchen G. Kimmick. “Self-efficacy for coping with symptoms moderates the relationship between physical symptoms and well-being in breast cancer survivors taking adjuvant endocrine therapy.” Support Care Cancer 22, no. 10 (October 2014): 2851–59. https://doi.org/10.1007/s00520-014-2269-1.
       Full Text  Link to Item
    • Daly, Mary B., Robert Pilarski, Jennifer E. Axilbund, Saundra S. Buys, Beth Crawford, Susan Friedman, Judy E. Garber, et al. “Genetic/familial high-risk assessment: breast and ovarian, version 1.2014.” J Natl Compr Canc Netw 12, no. 9 (September 2014): 1326–38. https://doi.org/10.6004/jnccn.2014.0127.
       Full Text  Link to Item
    • Anders, Carey, Allison M. Deal, Vandana Abramson, Minetta C. Liu, Anna M. Storniolo, John T. Carpenter, Shannon Puhalla, et al. “TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases.” Breast Cancer Res Treat 146, no. 3 (August 2014): 557–66. https://doi.org/10.1007/s10549-014-3039-y.
       Full Text  Link to Item
    • Gradishar, William J., Benjamin O. Anderson, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, et al. “Breast cancer version 3.2014.” J Natl Compr Canc Netw 12, no. 4 (April 2014): 542–90. https://doi.org/10.6004/jnccn.2014.0058.
       Full Text  Link to Item
    • Kamal, Arif H., Steve Power, Gloria Broadwater, Audrey R. Holland, and Paul K. Marcom. “Optimizing the quality of breast cancer biomarker use at Duke Cancer Institute.” J Natl Compr Canc Netw 12 Suppl 1, no. 0 1 (February 2014): S21–24. https://doi.org/10.6004/jnccn.2014.0209.
       Full Text  Link to Item
    • Anders, C., A. M. Deal, V. Abramson, M. C. Liu, A. M. Storniolo, J. T. Carpenter, S. Puhalla, et al. “TBCRC 018: Phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases.” Breast Cancer Research and Treatment 146, no. 3 (January 1, 2014): 557–66. https://doi.org/10.1007/s10549-014-3039-y.
       Full Text
    • Gwin, W. R., and P. K. Marcom. “Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: A prospective study.” Breast Diseases 25, no. 4 (January 1, 2014): 326–27. https://doi.org/10.1016/j.breastdis.2014.10.004.
       Full Text
    • Hamilton, Erika, Gretchen Kimmick, Judith Hopkins, P Kelly Marcom, Gloria Rocha, Renee Welch, Gloria Broadwater, and Kimberly Blackwell. “Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer.” Clin Breast Cancer 13, no. 6 (December 2013): 416–20. https://doi.org/10.1016/j.clbc.2013.08.003.
       Full Text  Link to Item
    • Peppercorn, Jeffrey, Erika Hamilton, Paul Kelly Marcom, Laura Beskow, and Gary H. Lyman. “Pharmacogenetic testing in the face of unclear clinical efficacy: lessons from cytochrome P450 2D6 for tamoxifen.” Cancer 119, no. 20 (October 15, 2013): 3703–9. https://doi.org/10.1002/cncr.28263.
       Full Text  Link to Item
    • Greenup, Rachel, Adam Buchanan, Wendy Lorizio, Keelia Rhoads, Salina Chan, Tracey Leedom, Robin King, et al. “Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort.” Ann Surg Oncol 20, no. 10 (October 2013): 3254–58. https://doi.org/10.1245/s10434-013-3205-1.
       Full Text  Link to Item
    • Jones, Lee W., Diane R. Fels, Miranda West, Jason D. Allen, Gloria Broadwater, William T. Barry, Lee G. Wilke, et al. “Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy.” Cancer Prev Res (Phila) 6, no. 9 (September 2013): 925–37. https://doi.org/10.1158/1940-6207.CAPR-12-0416.
       Full Text  Link to Item
    • Theriault, Richard L., Robert W. Carlson, Craig Allred, Benjamin O. Anderson, Harold J. Burstein, Stephen B. Edge, William B. Farrar, et al. “Breast cancer, version 3.2013: featured updates to the NCCN guidelines.” J Natl Compr Canc Netw 11, no. 7 (July 2013): 753–60. https://doi.org/10.6004/jnccn.2013.0098.
       Full Text  Link to Item
    • Edmond, Sara N., Rebecca A. Shelby, Gretchen G. Kimmick, Paul K. Marcom, Jeffrey M. Peppercorn, and Francis J. Keefe. “Symptom communication in breast cancer: relationships of holding back and self-efficacy for communication to symptoms and adjustment.” J Psychosoc Oncol 31, no. 6 (2013): 698–711. https://doi.org/10.1080/07347332.2013.835023.
       Full Text  Link to Item
    • Lyman, G. H., E. Culakova, M. S. Poniewierski, A. F. Wogu, W. Barry, G. S. Ginsburg, P. K. Marcom, et al. “Abstract P3-06-07: Ki67 as a Predictive Marker of Response to Neoadjuvant Chemotherapy in Patients with Early-Stage Breast Cancer (ESBC): A Systematic Review and Evidence Summary.” Cancer Research 72, no. 24_Supplement (December 15, 2012). https://doi.org/10.1158/0008-5472.sabcs12-p3-06-07.
       Full Text
    • Vaz-Luis, Ines, Rebecca A. Ottesen, Melissa E. Hughes, P Kelly Marcom, Beverly Moy, Hope S. Rugo, Richard L. Theriault, et al. “Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study.” Breast Cancer Res 14, no. 5 (October 1, 2012): R129. https://doi.org/10.1186/bcr3324.
       Full Text  Link to Item
    • Strickler, John H., Alexander N. Starodub, Jingquan Jia, Kellen L. Meadows, Andrew B. Nixon, Andrew Dellinger, Michael A. Morse, et al. “Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors.” Cancer Chemother Pharmacol 70, no. 2 (August 2012): 251–58. https://doi.org/10.1007/s00280-012-1911-1.
       Full Text  Link to Item
    • Carey, Lisa A., Hope S. Rugo, P Kelly Marcom, Erica L. Mayer, Francisco J. Esteva, Cynthia X. Ma, Minetta C. Liu, et al. “TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.” J Clin Oncol 30, no. 21 (July 20, 2012): 2615–23. https://doi.org/10.1200/JCO.2010.34.5579.
       Full Text  Link to Item
    • Carlson, Robert W., D Craig Allred, Benjamin O. Anderson, Harold J. Burstein, Stephen B. Edge, William B. Farrar, Andres Forero, et al. “Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines.” J Natl Compr Canc Netw 10, no. 7 (July 1, 2012): 821–29. https://doi.org/10.6004/jnccn.2012.0086.
       Full Text  Link to Item
    • Hassett, Michael J., Samuel M. Silver, Melissa E. Hughes, Douglas W. Blayney, Stephen B. Edge, James G. Herman, Clifford A. Hudis, et al. “Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer.” J Clin Oncol 30, no. 18 (June 20, 2012): 2218–26. https://doi.org/10.1200/JCO.2011.38.5740.
       Full Text  Link to Item
    • Ellis, Matthew J., Li Ding, Dong Shen, Jingqin Luo, Vera J. Suman, John W. Wallis, Brian A. Van Tine, et al. “Whole-genome analysis informs breast cancer response to aromatase inhibition.” Nature 486, no. 7403 (June 10, 2012): 353–60. https://doi.org/10.1038/nature11143.
       Full Text  Link to Item
    • Acharya, Chaitanya R., David S. Hsu, Carey K. Anders, Ariel Anguiano, Kelly H. Salter, Kelli S. Walters, Richard C. Redman, et al. “Retraction: Acharya CR, et al. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA. 2008;299(13):1574-1587.” Jama 307, no. 5 (February 1, 2012): 453. https://doi.org/10.1001/jama.2012.2.
       Full Text  Link to Item
    • Johnson, Karen S., Rex C. Bentley, P. Kelly Marcom, and Jay A. Baker. “Pseudoangiomatous stromal hyperplasia (PASH) causing massive breast enlargement: MRI findings.” Breast J 18, no. 6 (2012): 600–601. https://doi.org/10.1111/tbj.12026.
       Full Text  Link to Item
    • Culakova, E., M. S. Poniewierski, M. Huang, N. M. Kuderer, G. S. Ginsburg, W. Barry, P. K. Marcom, N. Ready, A. Abernethy, and G. H. Lyman. “P3-14-04: Assessment of Genomic Prognostic Signatures as Predictors of Response to Neoadjuvant Chemotherapy in Patients with Early Stage Breast Cancer.” Cancer Research 71, no. 24_Supplement (December 15, 2011). https://doi.org/10.1158/0008-5472.sabcs11-p3-14-04.
       Full Text
    • Hamilton, E. P., A. C. Hobeika, H. K. Lyerly, K. Owzar, G. Rocha, G. G. Kimmick, P. K. Marcom, J. M. Peppercorn, M. A. Morse, and K. L. Blackwell. “P1-13-03: Zoledronic Acid Induces an Immune Response in Breast Cancer Patients through Stimulation of Central Memory and Effector Memory gamma/delta T-Cells.” Cancer Research 71, no. 24_Supplement (December 15, 2011). https://doi.org/10.1158/0008-5472.sabcs11-p1-13-03.
       Full Text
    • Salter, K. H., C. R. Acharya, K. S. Walters, R. Redman, A. Anguiano, K. S. Garman, C. K. Anders, et al. “An Integrated Approach to the Prediction of Chemotherapeutic Response in Patients with Breast Cancer.” Plos One 6, no. 9 (December 1, 2011). https://doi.org/10.1371/journal.pone.0001908.
       Full Text
    • Herold, Christina I., Vijaya Chadaram, Bercedis L. Peterson, P Kelly Marcom, Judith Hopkins, Gretchen G. Kimmick, Justin Favaro, et al. “Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing.” Clin Cancer Res 17, no. 18 (September 15, 2011): 6061–70. https://doi.org/10.1158/1078-0432.CCR-11-1071.
       Full Text  Link to Item
    • Dominici, Laura, Julie Najita, Melissa Hughes, Joyce Niland, Paul Marcom, Yu-Ning Wong, Bradford Carter, et al. “Surgery of the primary tumor does not improve survival in stage IV breast cancer.” Breast Cancer Res Treat 129, no. 2 (September 2011): 459–65. https://doi.org/10.1007/s10549-011-1648-2.
       Full Text  Link to Item
    • Armstrong, Andrew J., Matthew S. Marengo, Sebastian Oltean, Gabor Kemeny, Rhonda L. Bitting, James D. Turnbull, Christina I. Herold, Paul K. Marcom, Daniel J. George, and Mariano A. Garcia-Blanco. “Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers.” Mol Cancer Res 9, no. 8 (August 2011): 997–1007. https://doi.org/10.1158/1541-7786.MCR-10-0490.
       Full Text  Link to Item
    • Bild, A. H., J. S. Parker, A. M. Gustafson, C. R. Acharya, K. A. Hoadley, C. Anders, P. K. Marcom, et al. “Correction: An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer.” Breast Cancer Research 13, no. 4 (July 12, 2011). https://doi.org/10.1186/bcr2909.
       Full Text
    • Ellis, Matthew J., Vera J. Suman, Jeremy Hoog, Li Lin, Jacqueline Snider, Aleix Prat, Joel S. Parker, et al. “Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.” J Clin Oncol 29, no. 17 (June 10, 2011): 2342–49. https://doi.org/10.1200/JCO.2010.31.6950.
       Full Text  Link to Item
    • Kuderer, N. M., E. Culakova, M. Huang, M. S. Poniewierski, G. S. Ginsburg, W. T. Barry, P. K. Marcom, N. Ready, A. P. Abernethy, and G. H. Lyman. “Quality appraisal of clinical validation studies for multigene prediction assays of chemotherapy response in early-stage breast cancer.” Journal of Clinical Oncology 29, no. 15_suppl (May 20, 2011): 3082–3082. https://doi.org/10.1200/jco.2011.29.15_suppl.3082.
       Full Text
    • Shelby, R. A., F. J. Keefe, S. N. Red, K. L. Blackwell, J. M. Peppercorn, P. K. Marcom, and G. G. Kimmick. “Symptom experiences and nonadherent medication-taking behaviors of breast cancer patients taking adjuvant hormone therapy.” Journal of Clinical Oncology 29, no. 15_suppl (May 20, 2011): 524–524. https://doi.org/10.1200/jco.2011.29.15_suppl.524.
       Full Text
    • Carlson, Robert W., D Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W Bradford Carter, Stephen B. Edge, John K. Erban, et al. “Invasive breast cancer.” J Natl Compr Canc Netw 9, no. 2 (February 2011): 136–222. https://doi.org/10.6004/jnccn.2011.0016.
       Full Text  Link to Item
    • Il’yasova, Dora, Kelly Kennedy, Ivan Spasojevic, Frances Wang, Adviye A. Tolun, Karel Base, Sarah P. Young, et al. “Individual responses to chemotherapy-induced oxidative stress.” Breast Cancer Res Treat 125, no. 2 (January 2011): 583–89. https://doi.org/10.1007/s10549-010-1158-7.
       Full Text  Link to Item
    • Rumble, Meredith E., Francis J. Keefe, Jack D. Edinger, Glenn Affleck, P Kelly Marcom, and Heather S. Shaw. “Contribution of cancer symptoms, dysfunctional sleep related thoughts, and sleep inhibitory behaviors to the insomnia process in breast cancer survivors: a daily process analysis.” Sleep 33, no. 11 (November 2010): 1501–9. https://doi.org/10.1093/sleep/33.11.1501.
       Full Text  Link to Item
    • Moorman, Patricia G., Edwin S. Iversen, P Kelly Marcom, Jeffrey R. Marks, Frances Wang, Frances Kathleen Cuningham Consortium for Research into Familial Breast Cancer, Eunjung Lee, et al. “Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis.” Breast Cancer Res Treat 124, no. 2 (November 2010): 441–51. https://doi.org/10.1007/s10549-010-0842-y.
       Full Text  Link to Item
    • Jones, Lee W., Pamela S. Douglas, Neil D. Eves, P Kelly Marcom, William E. Kraus, James E. Herndon, Brant A. Inman, Jason D. Allen, and Jeffrey Peppercorn. “Rationale and design of the Exercise Intensity Trial (EXCITE): A randomized trial comparing the effects of moderate versus moderate to high-intensity aerobic training in women with operable breast cancer.” Bmc Cancer 10 (October 6, 2010): 531. https://doi.org/10.1186/1471-2407-10-531.
       Full Text  Open Access Copy  Link to Item
    • Carlson, Robert W., D Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W Bradford Carter, Stephen B. Edge, John K. Erban, et al. “Breast cancer: noninvasive and special situations.” J Natl Compr Canc Netw 8, no. 10 (October 2010): 1182–1207. https://doi.org/10.6004/jnccn.2010.0087.
       Full Text  Link to Item
    • Il’yasova, Dora, Ivan Spasojevic, Frances Wang, Adviye A. Tolun, Karel Base, Sarah P. Young, P Kelly Marcom, et al. “Urinary biomarkers of oxidative status in a clinical model of oxidative assault.” Cancer Epidemiol Biomarkers Prev 19, no. 6 (June 2010): 1506–10. https://doi.org/10.1158/1055-9965.EPI-10-0211.
       Full Text  Link to Item
    • Barry, W., C. Acharya, M. B. Datto, H. K. Dressman, P. K. Marcom, N. Ready, G. S. Ginsburg, A. Potti, and J. R. Nevins. “Utilization of genomic signatures for chemotherapy response in prospective clinical studies.” Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): 10513–10513. https://doi.org/10.1200/jco.2010.28.15_suppl.10513.
       Full Text
    • Barry, William T., Dawn N. Kernagis, Holly K. Dressman, Ryan J. Griffis, J’vonne D. Hunter, John A. Olson, Jeff R. Marks, et al. “Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome.” J Clin Oncol 28, no. 13 (May 1, 2010): 2198–2206. https://doi.org/10.1200/JCO.2009.26.7245.
       Full Text  Link to Item
    • Daly, Mary B., Jennifer E. Axilbund, Saundra Buys, Beth Crawford, Carolyn D. Farrell, Susan Friedman, Judy E. Garber, et al. “Genetic/familial high-risk assessment: breast and ovarian.” J Natl Compr Canc Netw 8, no. 5 (May 2010): 562–94. https://doi.org/10.6004/jnccn.2010.0043.
       Full Text  Link to Item
    • Lipkus, Isaac M., Ellen Peters, Gretchen Kimmick, Vlayka Liotcheva, and Paul Marcom. “Breast cancer patients' treatment expectations after exposure to the decision aid program adjuvant online: the influence of numeracy.” Med Decis Making 30, no. 4 (2010): 464–73. https://doi.org/10.1177/0272989X09360371.
       Full Text  Link to Item
    • Tebbit, Christopher L., Jun Zhai, Brian R. Untch, Matthew J. Ellis, Holly K. Dressman, Rex C. Bentley, Jay A. Baker, et al. “Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care.” Breast Cancer Res Treat 118, no. 3 (December 2009): 635–43. https://doi.org/10.1007/s10549-008-0301-1.
       Full Text  Link to Item
    • Ellis, Matthew J., Feng Gao, Farrokh Dehdashti, Donna B. Jeffe, P Kelly Marcom, Lisa A. Carey, Maura N. Dickler, et al. “Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study.” Jama 302, no. 7 (August 19, 2009): 774–80. https://doi.org/10.1001/jama.2009.1204.
       Full Text  Link to Item
    • Il’yasova, Dora, Gabriel Mixon, Frances Wang, P Kelly Marcom, Jeffrey Marks, Ivan Spasojevich, Neal Craft, Francisco Arredondo, and Richard DiGiulio. “Markers of oxidative status in a clinical model of oxidative assault: a pilot study in human blood following doxorubicin administration.” Biomarkers 14, no. 5 (August 2009): 321–25. https://doi.org/10.1080/13547500902946757.
       Full Text  Link to Item
    • Olson, John A., G Thomas Budd, Lisa A. Carey, Lyndsay A. Harris, Laura J. Esserman, Gini F. Fleming, Paul K. Marcom, et al. “Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial.” J Am Coll Surg 208, no. 5 (May 2009): 906–14. https://doi.org/10.1016/j.jamcollsurg.2009.01.035.
       Full Text  Link to Item
    • Partridge, Ann H., A. C. Wolff, P. K. Marcom, P. A. Kaufman, L. Zhang, R. Gelman, C. Moore, et al. “The impact of sharing results of a randomized breast cancer clinical trial with study participants.” Breast Cancer Res Treat 115, no. 1 (May 2009): 123–29. https://doi.org/10.1007/s10549-008-0057-7.
       Full Text  Link to Item
    • Carlson, Robert W., D Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W Bradford Carter, Stephen B. Edge, John K. Erban, et al. “Breast cancer. Clinical practice guidelines in oncology.” J Natl Compr Canc Netw 7, no. 2 (February 2009): 122–92. https://doi.org/10.6004/jnccn.2009.0012.
       Full Text  Link to Item
    • Bild, Andrea H., Joel S. Parker, Adam M. Gustafson, Chaitanya R. Acharya, Katherine A. Hoadley, Carey Anders, P Kelly Marcom, et al. “An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer.” Breast Cancer Res 11, no. 4 (2009): R55. https://doi.org/10.1186/bcr2344.
       Full Text  Link to Item
    • Buchanan, A. H., C. S. Skinner, B. Calingaert, J. M. Schildkraut, R. H. King, and P. K. Marcom. “Cancer genetic counseling in rural north carolina oncology clinics: Program establishment and patient characteristics.” Community Oncology 6, no. 2 (January 1, 2009): 70–77. https://doi.org/10.1016/S1548-5315(11)70213-3.
       Full Text
    • Anders, C., P. K. Marcom, B. Peterson, L. Gu, S. Unruhe, R. Welch, P. Lyons, et al. “A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer (Cancer Investigation 26, 3, (286-295)).” Cancer Investigation 26, no. 10 (December 1, 2008): 1068. https://doi.org/10.1080/07357900802660220.
       Full Text
    • Herold, Christina I., and P Kelly Marcom. “Primary systemic therapy in breast cancer: past lessons and new approaches.” Cancer Invest 26, no. 10 (December 2008): 1052–59. https://doi.org/10.1080/07357900802123260.
       Full Text  Link to Item
    • Anders, Carey K., David S. Hsu, Gloria Broadwater, Chaitanya R. Acharya, John A. Foekens, Yi Zhang, Yixin Wang, et al. “Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.” J Clin Oncol 26, no. 20 (July 10, 2008): 3324–30. https://doi.org/10.1200/JCO.2007.14.2471.
       Full Text  Link to Item
    • Polite, Blase N., Constance Cirrincione, Gini F. Fleming, Donald A. Berry, Andrew Seidman, Hyman Muss, Larry Norton, et al. “Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B.” J Clin Oncol 26, no. 16 (June 1, 2008): 2659–65. https://doi.org/10.1200/JCO.2007.13.9782.
       Full Text  Link to Item
    • Liu, Minetta C., George D. Demetri, Donald A. Berry, Larry Norton, Gloria Broadwater, Nicholas J. Robert, David Duggan, et al. “Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.” Cancer Treat Rev 34, no. 3 (May 2008): 223–30. https://doi.org/10.1016/j.ctrv.2007.11.004.
       Full Text  Link to Item
    • Olson, John A., and Paul K. Marcom. “Benefit or bias? The role of surgery to remove the primary tumor in patients with metastatic breast cancer.” Ann Surg 247, no. 5 (May 2008): 739–40. https://doi.org/10.1097/SLA.0b013e3181706140.
       Full Text  Link to Item
    • Salter, Kelly H., Chaitanya R. Acharya, Kelli S. Walters, Richard Redman, Ariel Anguiano, Katherine S. Garman, Carey K. Anders, et al. “An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer.” Plos One 3, no. 4 (April 2, 2008): e1908. https://doi.org/10.1371/journal.pone.0001908.
       Full Text  Open Access Copy  Link to Item
    • Acharya, Chaitanya R., David S. Hsu, Carey K. Anders, Ariel Anguiano, Kelly H. Salter, Kelli S. Walters, Richard C. Redman, et al. “Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer.” Jama 299, no. 13 (April 2, 2008): 1574–87. https://doi.org/10.1001/jama.299.13.1574.
       Full Text  Link to Item
    • Seidman, Andrew D., Donald Berry, Constance Cirrincione, Lyndsay Harris, Hyman Muss, P Kelly Marcom, Grandella Gipson, et al. “Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.” J Clin Oncol 26, no. 10 (April 1, 2008): 1642–49. https://doi.org/10.1200/JCO.2007.11.6699.
       Full Text  Link to Item
    • Demark-Wahnefried, Wendy, L Douglas Case, Kimberly Blackwell, P Kelly Marcom, William Kraus, Noreen Aziz, Denise Clutter Snyder, Jeffrey K. Giguere, and Edward Shaw. “Results of a diet/exercise feasibility trial to prevent adverse body composition change in breast cancer patients on adjuvant chemotherapy.” Clin Breast Cancer 8, no. 1 (February 2008): 70–79. https://doi.org/10.3816/CBC.2008.n.005.
       Full Text  Link to Item
    • Anders, Carey K., Chaitanya R. Acharya, David S. Hsu, Gloria Broadwater, Katherine Garman, John A. Foekens, Yi Zhang, et al. “Age-specific differences in oncogenic pathway deregulation seen in human breast tumors.” Plos One 3, no. 1 (January 2, 2008): e1373. https://doi.org/10.1371/journal.pone.0001373.
       Full Text  Open Access Copy  Link to Item
    • Anders, Carey, P Kelly Marcom, Bercedis Peterson, Lin Gu, Sue Unruhe, Renee Welch, Peggy Lyons, et al. “A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer.” Cancer Invest 26, no. 3 (2008): 286–95. https://doi.org/10.1080/07357900701829777.
       Full Text  Link to Item
    • Porter, Laura S., Donald Baucom, Francis Keefe, Tina Gremore, Jennifer Kirby, and P Kelly Marcom. “WHAT ASPECTS OF MARITAL FUNCTIONING ARE IMPORTANT IN ADJUSTMENT TO BREAST CANCER?” Annals of Behavioral Medicine 33 (December 1, 2007): S141–S141.
       Link to Item
    • Morse, Michael A., Amy Hobeika, Takuya Osada, Donna Niedzwiecki, Paul Kelly Marcom, Kimberly L. Blackwell, Carey Anders, Gayathri R. Devi, H Kim Lyerly, and Timothy M. Clay. “Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2.” J Transl Med 5 (September 6, 2007): 42. https://doi.org/10.1186/1479-5876-5-42.
       Full Text  Link to Item
    • Burstein, Harold J., Aparna Keshaviah, Ari D. Baron, Ronald D. Hart, Rosemary Lambert-Falls, P Kelly Marcom, Rebecca Gelman, and Eric P. Winer. “Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study.” Cancer 110, no. 5 (September 1, 2007): 965–72. https://doi.org/10.1002/cncr.22885.
       Full Text  Link to Item
    • Lehman, Constance D., Claudine Isaacs, Mitchell D. Schnall, Etta D. Pisano, Susan M. Ascher, Paul T. Weatherall, David A. Bluemke, et al. “Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study.” Radiology 244, no. 2 (August 2007): 381–88. https://doi.org/10.1148/radiol.2442060461.
       Full Text  Link to Item
    • Marcom, P. K. “Genetic Nurse Counsellors Can Be An Acceptable and Cost-effective Alternative to Clinical Geneticists for Breast Cancer Risk Genetic Counselling. Evidence From Two Parallel Randomised Controlled Equivalence Trials.” Breast Diseases 18, no. 2 (July 1, 2007): 212. https://doi.org/10.1016/S1043-321X(07)80287-6.
       Full Text
    • Marcom, P Kelly, Claudine Isaacs, Lyndsay Harris, Zee Wang Wong, Aruna Kommarreddy, Nellie Novielli, Gretchen Mann, Yu Tao, and Matthew J. Ellis. “The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers.” Breast Cancer Res Treat 102, no. 1 (March 2007): 43–49. https://doi.org/10.1007/s10549-006-9307-8.
       Full Text  Link to Item
    • Bean, Gregory R., Catherine Ibarra Drendall, Vanessa K. Goldenberg, Joseph C. Baker, Michelle M. Troch, Carolyn Paisie, Lee G. Wilke, et al. “Hypermethylation of the breast cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast cancer risk.” Cancer Epidemiol Biomarkers Prev 16, no. 1 (January 2007): 50–56. https://doi.org/10.1158/1055-9965.EPI-06-0598.
       Full Text  Link to Item
    • Marcom, P Kelly, and Carmel S. Verrier. “Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer - The Morris/Carey article reviewed.” Oncology New York 20, no. 14 (December 1, 2006): 1775–76.
       Link to Item
    • Daly, Mary B., Jennifer E. Axilbund, Eileen Bryant, Saundra Buys, Charis Eng, Susan Friedman, Laura J. Esserman, et al. “Genetic/familial high-risk assessment: breast and ovarian.” J Natl Compr Canc Netw 4, no. 2 (February 2006): 156–76. https://doi.org/10.6004/jnccn.2006.0016.
       Full Text  Link to Item
    • Dressman, Holly K., Christopher Hans, Andrea Bild, John A. Olson, Eric Rosen, P Kelly Marcom, Vlayka B. Liotcheva, et al. “Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy.” Clin Cancer Res 12, no. 3 Pt 1 (February 1, 2006): 819–26. https://doi.org/10.1158/1078-0432.CCR-05-1447.
       Full Text  Link to Item
    • Burris, Howard A., Herbert I. Hurwitz, E Claire Dees, Afshin Dowlati, Kimberly L. Blackwell, Bert O’Neil, Paul K. Marcom, et al. “Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.” J Clin Oncol 23, no. 23 (August 10, 2005): 5305–13. https://doi.org/10.1200/JCO.2005.16.584.
       Full Text  Link to Item
    • Spector, Neil L., Wenle Xia, Howard Burris, Herbert Hurwitz, E Claire Dees, Afshin Dowlati, Bert O’Neil, et al. “Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.” J Clin Oncol 23, no. 11 (April 10, 2005): 2502–12. https://doi.org/10.1200/JCO.2005.12.157.
       Full Text  Link to Item
    • Bean, Gregory R., Victoria Scott, Lisa Yee, Brooke Ratliff-Daniel, Michelle M. Troch, Pearl Seo, Michelle L. Bowie, et al. “Retinoic acid receptor-beta2 promoter methylation in random periareolar fine needle aspiration.” Cancer Epidemiol Biomarkers Prev 14, no. 4 (April 2005): 790–98. https://doi.org/10.1158/1055-9965.EPI-04-0580.
       Full Text  Link to Item
    • Miller, Kathy D., Linnea I. Chap, Frankie A. Holmes, Melody A. Cobleigh, P Kelly Marcom, Louis Fehrenbacher, Maura Dickler, et al. “Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.” J Clin Oncol 23, no. 4 (February 1, 2005): 792–99. https://doi.org/10.1200/JCO.2005.05.098.
       Full Text  Link to Item
    • Gradishar, W. J., L. A. Meza, B. Amin, D. Samid, T. Hill, Y. M. Chen, E. E. Lower, P. K. Marcom, and S. Iqbal. “Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: A multicenter phase II study.” Women’S Oncology Review 4, no. 4 (December 1, 2004): 283–85. https://doi.org/10.1080/14733400500034472.
       Full Text
    • Jones, E. L., L. R. Prosnitz, M. W. Dewhirst, P. K. Marcom, P. H. Hardenbergh, L. B. Marks, D. M. Brizel, Z. Vujaskovic, and T. A. Buchholz. “Thermochemoradiotherapy improves oxygenation in locally advanced breast cancer.” Women’S Oncology Review 4, no. 3 (September 1, 2004): 221–22. https://doi.org/10.1080/14733400400012958.
       Full Text
    • Jones, Ellen L., Leonard R. Prosnitz, Mark W. Dewhirst, P Kelly Marcom, Patricia H. Hardenbergh, Lawrence B. Marks, David M. Brizel, and Zeljko Vujaskovic. “Thermochemoradiotherapy improves oxygenation in locally advanced breast cancer.” Clin Cancer Res 10, no. 13 (July 1, 2004): 4287–93. https://doi.org/10.1158/1078-0432.CCR-04-0133.
       Full Text  Link to Item
    • Gradishar, William J., Luis A. Meza, Bipinkumar Amin, Dvorit Samid, Todd Hill, Yin-Miao Chen, Elyse E. Lower, and P Kelly Marcom. “Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study.” J Clin Oncol 22, no. 12 (June 15, 2004): 2321–27. https://doi.org/10.1200/JCO.2004.12.128.
       Full Text  Link to Item
    • Burstein, Harold J., Lyndsay N. Harris, P Kelly Marcom, Rosemary Lambert-Falls, Kathleen Havlin, Beth Overmoyer, Robert J. Friedlander, et al. “Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.” J Clin Oncol 21, no. 15 (August 1, 2003): 2889–95. https://doi.org/10.1200/JCO.2003.02.018.
       Full Text  Link to Item
    • Partridge, Ann H., Harold J. Burstein, Rebecca S. Gelman, P Kelly Marcom, and Eric P. Winer. “Do patients participating in clinical trials want to know study results?” J Natl Cancer Inst 95, no. 6 (March 19, 2003): 491–92. https://doi.org/10.1093/jnci/95.6.491.
       Full Text  Link to Item
    • Dietze, Eric C., L Elizabeth Caldwell, Kelly Marcom, Steven J. Collins, Lisa Yee, Karen Swisshelm, Katherine B. Hobbs, Gregory R. Bean, and Victoria L. Seewaldt. “Retinoids and retinoic acid receptors regulate growth arrest and apoptosis in human mammary epithelial cells and modulate expression of CBP/p300.” Microsc Res Tech 59, no. 1 (October 1, 2002): 23–40. https://doi.org/10.1002/jemt.10174.
       Full Text  Link to Item
    • Skinner, Celette Sugg, Joellen M. Schildkraut, Donald Berry, Brian Calingaert, P Kelly Marcom, Jeremy Sugarman, Eric P. Winer, J Dirk Iglehart, P Andrew Futreal, and Barbara K. Rimer. “Pre-counseling education materials for BRCA testing: does tailoring make a difference?” Genet Test 6, no. 2 (2002): 93–105. https://doi.org/10.1089/10906570260199348.
       Full Text  Link to Item
    • Demark-Wahnefried, W., B. L. Peterson, E. P. Winer, L. Marks, N. Aziz, P. K. Marcom, K. Blackwell, and B. K. Rimer. “Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy.” J Clin Oncol 19, no. 9 (May 1, 2001): 2381–89. https://doi.org/10.1200/JCO.2001.19.9.2381.
       Full Text  Link to Item
    • Miron, A., J. M. Schildkraut, B. K. Rimer, E. P. Winer, C. Sugg Skinner, P. A. Futreal, D. Culler, et al. “Testing for hereditary breast and ovarian cancer in the southeastern United States.” Ann Surg 231, no. 5 (May 2000): 624–34. https://doi.org/10.1097/00000658-200005000-00002.
       Full Text  Link to Item
    • Demark-Wahnefried, W., S. Halabi, V. Hars, E. Winer, P. K. Marcom, K. Blackwell, L. Harris, and B. K. Rimer. “Increased weight & body fatness associated with chemotherapy for breast cancer ... & what can be done?” Cancer Epidemiology Biomarkers & Prevention 9, no. 2 (February 1, 2000): 236–236.
       Link to Item
    • Burstein, H. J., M. J. Ramirez, W. P. Petros, K. D. Clarke, M. A. Warmuth, P. K. Marcom, U. A. Matulonis, L. M. Parker, L. N. Harris, and E. P. Winer. “Phase I study of Doxil and vinorelbine in metastatic breast cancer.” Ann Oncol 10, no. 9 (September 1999): 1113–16. https://doi.org/10.1023/a:1008323200102.
       Full Text  Link to Item
    • Ortel, T. L., L. A. Charles, F. G. Keller, P. K. Marcom, H. N. Oldham, W. H. Kane, and B. G. Macik. “Topical thrombin and acquired coagulation factor inhibitors: clinical spectrum and laboratory diagnosis.” Am J Hematol 45, no. 2 (February 1994): 128–35. https://doi.org/10.1002/ajh.2830450206.
       Full Text  Link to Item
    • Kirkland, K. B., P. K. Marcom, D. J. Sexton, J. S. Dumler, and D. H. Walker. “Rocky Mountain spotted fever complicated by gangrene: report of six cases and review.” Clin Infect Dis 16, no. 5 (May 1993): 629–34. https://doi.org/10.1093/clind/16.5.629.
       Full Text  Link to Item
    • Noebels, J. L., P. K. Marcom, and M. H. Jalilian-Tehrani. “Sodium channel density in hypomyelinated brain increased by myelin basic protein gene deletion.” Nature 352, no. 6334 (August 1, 1991): 431–34. https://doi.org/10.1038/352431a0.
       Full Text  Link to Item

  • Book Sections

    • Marcom, P. K. “Breast Cancer.” In Genomic and Precision Medicine: Primary Care: Third Edition, 181–94, 2017. https://doi.org/10.1016/B978-0-12-800685-6.00010-2.
       Full Text

  • Other Articles

    • Aziz, Hamza, P Kelly Marcom, and E Shelley Hwang. “Implications of HER2-targeted therapy on extent of surgery for early-stage breast cancer.” Ann Surg Oncol, May 2015. https://doi.org/10.1245/s10434-015-4503-6.
       Full Text  Link to Item

  • Conference Papers

    • Mayer, Erica L., Vandana Gupta Abramson, Rachel Catherine Jankowitz, Carla Isadora Falkson, Paul Kelly Marcom, Tiffany A. Traina, Lisa A. Carey, et al. “TBCRC 030: A randomized phase II study of preoperative cisplatin versus paclitaxel in TNBC—Evaluating the homologous recombination deficiency (HRD) biomarker.” In Journal of Clinical Oncology, 37:507–507. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.507.
       Full Text
    • Sammons, Sarah, Grace Anderson, Suzanne Wardell, Donald P. McDonnell, Paul Kelly Marcom, and Kris Wood. “Combination mTORC1/2 and BCL- X_L inhibition in endocrine and CDK4/6-resistant estrogen receptor-positive breast cancer.” In Journal of Clinical Oncology, 37:e14653–e14653. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.e14653.
       Full Text
    • Sammons, Sarah, Tira Jing Ying Tan, Tiffany A. Traina, Sung-Bae Kim, Young-Hyuck Im, Carol Bachelder, Paul Kelly Marcom, and Rebecca Alexandra Dent. “Dora: A randomized phase II multicenter maintenance study of olaparib alone or olaparib in combination with durvalumab in platinum responsive advanced triple-negative breast cancer (aTNBC).” In Journal of Clinical Oncology, 37:TPS1113–TPS1113. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.tps1113.
       Full Text
    • Force, J., J. Plichta, I. Stashko, G. Kimmick, K. Westbrook, S. Sammons, S. Hwang, et al. “Abstract P3-08-07: Distinct biological signatures describe differences in BRCA mutated subgroups.” In Cancer Research, Vol. 79. American Association for Cancer Research (AACR), 2019. https://doi.org/10.1158/1538-7445.sabcs18-p3-08-07.
       Full Text
    • Davidson, B. A., J. Ehrisman, S. D. Reed, J. Yang, F. R. Johnson, A. H. Buchanan, P. K. Marcom, and L. J. Havrilesky. “PMD180 - THE VALUE TO WOMEN WITH OVARIAN CANCER OF GENE VARIANTS WITH KNOWN AND UNKNOWN SIGNIFICANCE: A DISCRETE CHOICE EXPERIMENT.” In Value in Health, 21:S274–S274. Elsevier BV, 2018. https://doi.org/10.1016/j.jval.2018.09.1629.
       Full Text
    • Force, Jeremy, Eda Holl, Michael Brown, Paul Kelly Marcom, Lars Grimm, David Boczkowski, Victoria Frazier, et al. “Recombinant oncolytic poliovirus combined with checkpoint blockade for breast cancer therapy.” In Journal of Clinical Oncology, 36:e12641–e12641. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.e12641.
       Full Text
    • Tolaney, Sara M., William Thomas Barry, Hao Guo, Deborah Dillon, Chau T. Dang, Denise A. Yardley, Beverly Moy, et al. “Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC).” In Journal of Clinical Oncology, 35:511–511. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.511.
       Full Text
    • Diéras, V., H. S. Han, M. E. Robson, M. Palácová, P. K. Marcom, A. Jager, I. Bondarenko, et al. “Abstract P4-22-02: Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer.” In Cancer Research, Vol. 77. American Association for Cancer Research (AACR), 2017. https://doi.org/10.1158/1538-7445.sabcs16-p4-22-02.
       Full Text
    • Force, J., S. Abbott, G. Broadwater, G. Kimmick, K. Westbrook, S. Hwang, N. Kauff, et al. “Abstract P2-04-19: Elucidating the tumor immune microenvironment phenotype in early stage untreated BRCA mutated breast cancer patients.” In Cancer Research, Vol. 77. American Association for Cancer Research (AACR), 2017. https://doi.org/10.1158/1538-7445.sabcs16-p2-04-19.
       Full Text
    • Han, H. S., V. Diéras, M. E. Robson, M. Palácová, P. K. Marcom, A. Jager, I. Bondarenko, et al. “Abstract S2-05: Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: A randomized, phase 2 study.” In Cancer Research, Vol. 77. American Association for Cancer Research (AACR), 2017. https://doi.org/10.1158/1538-7445.sabcs16-s2-05.
       Full Text
    • Paoletti, C., M. M. Regan, M. C. Liu, P. K. Marcom, L. L. Hart, J. W. Smith, K. L. Tedesco, et al. “Abstract P1-01-01: Circulating tumor cell number and CTC-endocrine therapy index predict clinical outcomes in ER positive metastatic breast cancer patients: Results of the COMETI Phase 2 trial.” In Cancer Research, Vol. 77. American Association for Cancer Research (AACR), 2017. https://doi.org/10.1158/1538-7445.sabcs16-p1-01-01.
       Full Text
    • Harowicz, M. R., J. R. Marks, P. Kelly Marcom, and M. A. Mazurowski. “Can BI-RADS features on mammography be used as a surrogate for expensive genomic testing in breast cancer patients?” In Progress in Biomedical Optics and Imaging  Proceedings of Spie, Vol. 10136, 2017. https://doi.org/10.1117/12.2255866.
       Full Text
    • Force, Jeremy Meyer, Lynn Jackson Howie, Sara Abbott, Rex C. Bentley, Paul K. Marcom, Gretchen Genevieve Kimmick, Kelly E. Westbrook, et al. “Increased FoxP3 and PD-L1 in non-pCR tissue from early stage HER2 positive breast cancer patients treated with trastuzumab-pertuzumab based regimens.” In Journal of Clinical Oncology, 34:602–602. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.602.
       Full Text
    • Harnden, K. K., G. G. Kimmick, P. K. Marcom, K. E. Westbrook, and K. L. Blackwell. “Abstract P6-04-11: The foundation one assay influences clinical decision making in metastatic breast cancer.” In Cancer Research, Vol. 76. American Association for Cancer Research (AACR), 2016. https://doi.org/10.1158/1538-7445.sabcs15-p6-04-11.
       Full Text
    • Howie, L. J., P. K. Marcom, D. L. Topping, J. Force, R. Emerson, N. A. Bhavsar, S. E. Abbott, M. Parks, H. S. Robins, and K. L. Blackwell. “Abstract P4-14-16: T-cell clonality increases after neoadjuvant treatment with trastuzumab and pertuzumab.” In Cancer Research, Vol. 76. American Association for Cancer Research (AACR), 2016. https://doi.org/10.1158/1538-7445.sabcs15-p4-14-16.
       Full Text
    • Obeng-Gyasi, S., I. Stashko, S. Power, P. K. Marcom, and E. S. Hwang. “Implementation of the Distress Thermometer Among Surgical Breast Cancer Patients at a Comprehensive Breast Center.” In Annals of Surgical Oncology, 23:S71–S71. SPRINGER, 2016.
       Link to Item
    • Strickler, John H., Fatima A. Rangwala, Christel Rushing, Donna Niedzwiecki, Ivy Altomare, Hope Elizabeth Uronis, Shiaowen David Hsu, et al. “X-TRAP: Phase I/II study of capecitabine (X) plus ziv-aflibercept (TRAP) in metastatic colorectal cancer (mCRC).” In Journal of Clinical Oncology, 34:687–687. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.4_suppl.687.
       Full Text
    • Irwin, Blair, Gretchen Kimmick, Ivy Altomare, P Kelly Marcom, Kevin Houck, S Yousuf Zafar, and Jeffrey Peppercorn. “Patient experience and attitudes toward addressing the cost of breast cancer care.” In Oncologist, 19:1135–40, 2014. https://doi.org/10.1634/theoncologist.2014-0117.
       Full Text  Link to Item
    • Tseng, Y. D., H. Uno, M. E. Hughes, J. C. Niland, Y. Wong, R. Theriault, P. K. Marcom, et al. “Association Between Breast Cancer Biological Subtype and Risk of Locoregional Recurrence A Mastectomy in Node-Negative Patients.” In International Journal of Radiation Oncology*Biology*Physics, 90:S244–S244. Elsevier BV, 2014. https://doi.org/10.1016/j.ijrobp.2014.05.863.
       Full Text
    • Mayer, Erica L., Ines Vaz-Luis, Andrea L. Richardson, Charles M. Perou, Nadine M. Tung, Vandana Gupta Abramson, Carey K. Anders, et al. “TBCRC030: A randomized, phase II study of preoperative cisplatin versus paclitaxel in patients (pts) with BRCA1/2-proficient triple-negative breast cancer (TNBC)—Evaluating the homologous recombination deficiency (HRD) biomarker.” In Journal of Clinical Oncology, 32:TPS1145–TPS1145. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.tps1145.
       Full Text
    • Zhang, Tian, Steve Power, Paul K. Marcom, and Arif Kamal. “Is advanced imaging in early-stage breast cancer ever warranted? Exploring benchmarks for an ASCO Choosing Wisely quality measure.” In Journal of Clinical Oncology, 32:6503–6503. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.6503.
       Full Text
    • Blackwell, K. L., E. P. Hamilton, P. K. Marcom, J. Peppercorn, N. Spector, G. Kimmick, J. Hopkins, et al. “Abstract S4-03: Exome sequencing reveals clinically actionable mutations in the pathogenesis and metastasis of triple negative breast cancer.” In Cancer Research, Vol. 73. American Association for Cancer Research (AACR), 2013. https://doi.org/10.1158/0008-5472.sabcs13-s4-03.
       Full Text
    • Dees, E. C., P. K. Marcom, A. Snavely, J. Noe, C. K. Anders, K. Blackwell, G. Kimmick, et al. “Abstract P2-16-13: Phase I dose escalation clinical trial of the PI3K inhibitor BKM120 and capecitabine (C) in metastatic breast cancer (MBC).” In Cancer Research, Vol. 73. American Association for Cancer Research (AACR), 2013. https://doi.org/10.1158/0008-5472.sabcs13-p2-16-13.
       Full Text
    • Ruddy, K. J., S. M. Tolaney, H. Guo, C. T. Dang, D. A. Yardley, B. Moy, P. K. Marcom, et al. “Abstract P3-08-05: Chemotherapy-related amenorrhea on adjuvant paclitaxel-trastuzumab (APT trial).” In Cancer Research, Vol. 73. American Association for Cancer Research (AACR), 2013. https://doi.org/10.1158/0008-5472.sabcs13-p3-08-05.
       Full Text
    • Tolaney, S. M., W. T. Barry, C. T. Dang, D. A. Yardley, B. Moy, P. K. Marcom, K. S. Albain, et al. “Abstract S1-04: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC).” In Cancer Research, Vol. 73. American Association for Cancer Research (AACR), 2013. https://doi.org/10.1158/0008-5472.sabcs13-s1-04.
       Full Text
    • Power, Steve, Rhonda Lynn Bitting, P Kelly Marcom, and Arif Kamal. “Identifying benchmarks for ASCO's "Choosing Wisely" measures that address low-value imaging in early-stage prostate and breast cancer.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013. https://doi.org/10.1200/jco.2013.31.31_suppl.194.
       Full Text  Link to Item
    • Hamilton, Erika Paige, Donna L. Topping, Jeffrey M. Peppercorn, P Kelly Marcom, Gretchen Genevieve Kimmick, Erin Duff, Constance T. Cirrincione, and Kimberly L. Blackwell. “Clinical impact of febrile neutropenia (FIN) increase among patients receiving adjuvant docetaxel/cyclophosphamide (TC) chemotherapy compared to TC plus pegfilgrastim for breast cancer.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
       Link to Item
    • Anders, Carey K., Allison Mary Deal, Vandana Gupta Abramson, Minetta C. Liu, Anna Maria Storniolo, John T. Carpenter, Shannon Puhalla, et al. “TBCRC 018: Phase II study of iniparib plus chemotherapy to treat triple-negative breast cancer (TNBC) central nervous system (CNS) metastases (mets).” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
       Link to Item
    • Greenup, Rachel, P Kelly Marcom, Jane McLennan, Adam Buchanan, Robin King, Beth Crawford, Yunn-Yi Chen, Aimee Mackey, and E Shelley Hwang. “Impact of Race in Prevalence of BRCA Mutations Among Women With Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling Cohort.” In Annals of Surgical Oncology, 20:17–17. SPRINGER, 2013.
       Link to Item
    • Edmond, Sara N., Jamie M. Farquhar, Rebecca A. Shelby, Gretchen G. Kimmick, Paul K. Marcom, Jeffrey M. Peppercorn, Kimberly L. Blackwell, and Francis J. Keefe. “RELATIONSHIPS BETWEEN SELF-EFFICACY FOR COMMUNICATION WITH ONE'S PHYSICIAN AND MEASURES OF WELL-BEING, CONCERNS ABOUT TAKING MEDICATIONS, AND MEDICATION ADHERENCE IN BREAST CANCER PATIENTS RECEIVING ADJUVANT ENDOCRINE THERAPY.” In Annals of Behavioral Medicine, 45:S178–S178. SPRINGER, 2013.
       Link to Item
    • Greenup, R. A., T. Breslin, S. B. Edge, M. E. Hughes, E. S. Hwang, C. Laronga, P. Marcom, et al. “Outcomes after Mastectomy for Node-positive Breast Cancer: Comparison of Women Treated With and Without Completion Axillary Dissection at NCCN Cancer Centers.” In Annals of Surgical Oncology, 20:S9–S9. SPRINGER, 2013.
       Link to Item
    • Barry, W. T., P. K. Marcom, J. Geradts, and M. B. Datto. “Abstract P4-09-01: Retrospective evaluation of precision of gene-expression-based signatures of prognosis and tumor biology in replicate surgical biospecimens from patients with breast cancer.” In Cancer Research, Vol. 72. American Association for Cancer Research (AACR), 2012. https://doi.org/10.1158/0008-5472.sabcs12-p4-09-01.
       Full Text
    • Breslin, T., S. Hwang, R. Mamet, M. Hughes, R. Otteson, S. Edge, B. Moy, et al. “Patterns of definitive axillary management in the era prior to reporting ACOSOG Z0011: comparison between NCCN Centers and hospitals in Michigan.” In Cancer Research, Vol. 72. AMER ASSOC CANCER RESEARCH, 2012.
       Link to Item
    • Vandergrift, J. L., T. M. Breslin, J. C. Niland, S. B. Edge, A. C. Wolff, P. K. Marcom, H. S. Rugo, et al. “Abstract P1-13-05: The association between timing in adjuvant chemotherapy administration and overall survival for women with breast cancer within the National Comprehensive Cancer Network (NCCN).” In Cancer Research, Vol. 72. American Association for Cancer Research (AACR), 2012. https://doi.org/10.1158/0008-5472.sabcs12-p1-13-05.
       Full Text
    • Luis, Ines Maria Vaz Duarte, Rebecca A. Ottesen, Melissa E. Hughes, P Kelly Marcom, Beverly Moy, Hope S. Rugo, Richard L. Theriault, et al. “Impact of hormone receptor (HR) status on clinicopathological features, patterns of recurrence, and clinical outcomes among patients (pts) with human epidermal growth factor receptor-2 positive (HER2) breast cancer (BC) in the National Comprehensive Cancer Network (NCCN).” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
       Link to Item
    • Ellis, Matthew J., Ding Li, Dong Shen, Jingqin Luo, Vera J. Suman, John W. Wallis, Brian A. Van Tine, et al. “Abstract LB-423: Whole genome comparisons of pre- and post- aromatase inhibitor treatment in estrogen receptor positive breast cancer.” In Cancer Research, Vol. 72. American Association for Cancer Research (AACR), 2012. https://doi.org/10.1158/1538-7445.am2012-lb-423.
       Full Text
    • Olson, J. A., B. V. Gildy, G. Unzeitig, P. K. Marcom, J. M. Guenther, K. Deshryver, C. Allred, et al. “Neoadjuvant Aromatase Inhibitor Therapy Permits Breast Conservation in Postmenopausal Women with Large, Estrogen Receptor (ER)-Rich Breast Cancer Facing Mastectomy: Results from The American College of Surgeons Oncology Group (ACOSOG) Z1031 Trial.” In Annals of Surgical Oncology, 19:S6–7. SPRINGER, 2012.
       Link to Item
    • Lyman, G. H., E. Culakova, M. S. Poniewierski, M. Huang, W. Barry, G. Ginsburg, A. Abernethy, P. K. Marcom, N. Ready, and N. M. Kuderer. “P5-13-17: Multigene Signature Assays in Patients with Early-Stage Breast Cancer (ESBC) Receiving Neoadjuvant Chemotherapy: An NCI-Funded Systematic Review and Evidence Summary of Predictive Performance.” In Cancer Research, Vol. 71. American Association for Cancer Research (AACR), 2011. https://doi.org/10.1158/0008-5472.sabcs11-p5-13-17.
       Full Text
    • Kamal, A., T. Zhang, A. Schneider, K. Patel, E. P. Hamilton, P. K. Marcom, and J. M. Peppercorn. “Outcomes in phase II trials of metastatic breast cancer: Where is the bar?” In Journal of Clinical Oncology, 29:2590–2590. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.15_suppl.2590.
       Full Text
    • Lyman, G. H., N. M. Kuderer, P. K. Marcom, and J. A. Olson, Jr. “Abstract PD06-09: Sentinel Node Biopsy Versus Axillary Lymph Node Dissection in Early-Stage Breast Cancer: A Meta-Analysis of Randomized Controlled Trials.” In Cancer Research, Vol. 70. American Association for Cancer Research (AACR), 2010. https://doi.org/10.1158/0008-5472.sabcs10-pd06-09.
       Full Text
    • Ellis, M. J., G. Babiera, G. W. Unzeitig, P. K. Marcom, J. M. Guenther, F. K. Deshryver, D. C. Allred, V. Suman, K. Hunt, and J. A. Olson. “ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast cancer.” In Journal of Clinical Oncology, 28:LBA513–LBA513. American Society of Clinical Oncology (ASCO), 2010. https://doi.org/10.1200/jco.2010.28.18_suppl.lba513.
       Full Text
    • Hamilton, E. P., G. G. Kimmick, N. Desai, S. Singh, J. O. Hopkins, P. K. Marcom, V. Chadaram, R. Welch, V. N. Trieu, and K. L. Blackwell. “Use of SPARC, EGFR, and VEGFR expression to predict response to nab-paclitaxel (nabP)/carboplatin (C)/bevacizumab (B) chemotherapy in triple-negative metastatic breast cancer (TNMBC).” In Journal of Clinical Oncology, 28:1109–1109. American Society of Clinical Oncology (ASCO), 2010. https://doi.org/10.1200/jco.2010.28.15_suppl.1109.
       Full Text
    • Hassett, M. J., J. C. Niland, M. E. Hughes, R. L. Theriault, D. W. Blayney, Y. Wong, C. Hudis, P. K. Marcom, C. Laronga, and J. C. Weeks. “Gene expression profile testing for breast cancer: Patterns and predictors of use and impact on chemotherapy.” In Journal of Clinical Oncology, 28:566–566. American Society of Clinical Oncology (ASCO), 2010. https://doi.org/10.1200/jco.2010.28.15_suppl.566.
       Full Text
    • Marcom, P. K., W. Barry, M. B. Datto, J. Geradts, J. A. Olson, J. Marks, G. H. Lyman, A. Potti, G. S. Ginsburg, and J. R. Nevins. “A randomized phase II trial evaluating the performance of genomic expression profiles to direct the use of preoperative chemotherapy for early-stage breast cancer.” In Journal of Clinical Oncology, 28:TPS102–TPS102. American Society of Clinical Oncology (ASCO), 2010. https://doi.org/10.1200/jco.2010.28.15_suppl.tps102.
       Full Text
    • Peppercorn, J. M., E. P. Hamilton, L. Beskow, I. Lipkus, P. K. Marcom, and G. H. Lyman. “Factors influencing use of genetic tests in clinical practice among U.S. oncologists.” In Journal of Clinical Oncology, 28:6067–6067. American Society of Clinical Oncology (ASCO), 2010. https://doi.org/10.1200/jco.2010.28.15_suppl.6067.
       Full Text
    • Peppercorn, J., E. Hamilton, S. Qiu, I. Lipkus, P. K. Marcom, L. Beskow, and G. Lyman. “Practice and Attitudes towards CYP2D6 Testing for Patients on Tamoxifen among US Oncologists.” In Cancer Research, 69:563S-563S. AMER ASSOC CANCER RESEARCH, 2009.
       Link to Item
    • Ellis, M. J., F. Dehdahti, A. Kommareddy, S. Jamalabadi-Majidi, R. Crowder, D. B. Jeffe, F. Gao, et al. “A randomized phase 2 trial of low dose (6 mg daily) versus high dose (30 mg daily) estradiol for patients with estrogen receptor positive aromatase inhibitor resistant advanced breast cancer.” In Cancer Research, 69:67S-68S. AMER ASSOC CANCER RESEARCH, 2009.
       Link to Item
    • Herold, C., P. K. Marcom, J. Hopkins, E. A. McKeen, R. A. Welch, V. Chadaram, J. Spohn, et al. “A phase II study to optimize dasatinib dosing in metastatic breast cancer patients using real-time pharmacodynamic tissue and urinary biomarkers.” In Cancer Research, 69:238S-239S. AMER ASSOC CANCER RESEARCH, 2009.
       Link to Item
    • Rugo, H. S., L. A. Carey, E. Mayer, P. K. Marcom, M. Liu, C. Ma, A. M. Storniolo, et al. “Assays of circulating tumor cells and outcome in the triple-negative breast cancer trial TBCRC001.” In Cancer Research, 69:360S-361S. AMER ASSOC CANCER RESEARCH, 2009.
       Link to Item
    • Il’yasova, Dora, Ivan Spasojevic, Frances Wang, Adviye Tolun, Karel Base, Sarah Young, P Kelly Marcom, et al. “How to Measure Oxidative Status in Humans? Part II.” In Free Radical Biology and Medicine, 47:S170–S170. ELSEVIER SCIENCE INC, 2009.
       Link to Item
    • Nam, J., J. L. Hubbs, P. K. Marcom, L. R. Prosnitz, and L. B. Marks. “Decisions Regarding Post-mastectomy Radiation Therapy (PMRT) Based on Post-chemotherapy Pathologic Stage Reduces the Potential Survival Benefits of PMRT: A Markov-model Based Decision Analysis.” In International Journal of Radiation Oncology*Biology*Physics, 72:S179–S179. Elsevier BV, 2008. https://doi.org/10.1016/j.ijrobp.2008.06.741.
       Full Text
    • Barry, W. T., M. Datto, J. Geradts, T. Foster, J. Olson, P. K. Marcom, H. K. Dressman, J. R. Nevins, G. Ginsburg, and A. Potti. “Genomic-based signatures of chemosensitivity and ER/HER2 status in biologic replicate breast cancer samples.” In Journal of Clinical Oncology, 26:11068–11068. American Society of Clinical Oncology (ASCO), 2008. https://doi.org/10.1200/jco.2008.26.15_suppl.11068.
       Full Text
    • Carey, L. A., H. S. Rugo, P. K. Marcom, W. Irvin, M. Ferraro, E. Burrows, X. He, C. M. Perou, and E. P. Winer. “TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer.” In Journal of Clinical Oncology, 26:1009–1009. American Society of Clinical Oncology (ASCO), 2008. https://doi.org/10.1200/jco.2008.26.15_suppl.1009.
       Full Text
    • Salter, K. H., B. A. Perez, C. R. Acharya, K. S. Walters, A. Anguiano, C. K. Anders, H. K. Dressman, P. K. Marcom, J. R. Nevins, and A. Potti. “Integration of clinico-pathologic variables, mRNA, and microRNA profiles represents an optimal strategy to predict sensitivity to chemotherapeutic agents in breast cancer.” In Journal of Clinical Oncology, 26:14567–14567. American Society of Clinical Oncology (ASCO), 2008. https://doi.org/10.1200/jco.2008.26.15_suppl.14567.
       Full Text
    • Madhav, P., S. Cutler, D. Crotty, K. Perez, R. Mckinley, P. Marcom, T. Wong, and M. Tornai. “TU‐C‐332‐04: Pilot Patient Studies Using a Dedicated Dual‐Modality SPECT‐CT System for Breast Imaging.” In Medical Physics, 35:2894, 2008. https://doi.org/10.1118/1.2962498.
       Full Text
    • Il’yasova, Dora, Gabriel Mixon, P Kelly Marcom, Jeffrey Marks, Ivan Spasojevich, Neal Craft, Francisco Arredondo, and Richard Di Giulio. “How to Measure Oxidative Status in Humans?” In Free Radical Biology and Medicine, 45:S54–S54. ELSEVIER SCIENCE INC, 2008.
       Link to Item
    • Carey, L. A., E. Mayer, P. K. Marcom, H. Rugo, M. Liu, C. Ma, M. Rimawi, et al. “TBCRC 001: EGFR inhibition with cetuximab in metastatic triple negative (basal-like) breast cancer.” In Breast Cancer Research and Treatment, 106:S32–S32. SPRINGER, 2007.
       Link to Item
    • Anders, C. K., S. D. Hsu, C. R. Acharya, Y. Zhang, Y. Wang, J. A. Foekens, P. K. Marcom, et al. “Molecular signatures characterize early stage breast cancer arising in young women and have prognostic and therapeutic implications independent of ER status.” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.
       Link to Item
    • Lipkus, I. M., G. G. Kimmick, S. Y. Chui, D. L. Fifield, L. A. Werner, and P. K. Marcom. “Relationship between numeracy and breast cancer patients' estimates of adjuvant treatment benefit.” In Journal of Clinical Oncology, 24:24S-24S. AMER SOC CLINICAL ONCOLOGY, 2006.
       Link to Item
    • Burstein, H. J., A. Keshaviah, A. Baron, R. Hart, R. Lambert-Falls, P. K. Marcom, R. Gelman, and E. P. Winer. “Trastuzumab and vinorelbine or taxane chemotherapy for HER2+metastatic breast cancer: The TRAVIOTA study.” In Journal of Clinical Oncology, 24:40S-40S. AMER SOC CLINICAL ONCOLOGY, 2006.
       Link to Item
    • Partridge, A. H., A. C. Wolff, P. K. Marcom, P. A. Kaufman, C. Moore, D. Lake, G. Fleming, H. S. Rugo, D. Collyar, and E. P. Winer. “Study participants' perceptions of the process and impact of receiving results of N9831.” In Journal of Clinical Oncology, 24:7S-7S. AMER SOC CLINICAL ONCOLOGY, 2006.
       Link to Item
    • Rumble, M., F. J. Keefe, J. D. Edinger, L. S. Porter, J. L. Garst, and P. K. Marcom. “Relationship of dysfunctional sleep-related thoughts and behaviors, pre-sleep arousal, cancer symptoms, and mood to sleep in breast and lung cancer patients with insomnia.” In Sleep, 29:A251–A251. OXFORD UNIV PRESS INC, 2006.
       Link to Item
    • Petros, W., G. Broadwater, M. Colvin, P. K. Marcom, N. Chao, and J. Marks. “Association between CYP3A5 genotype and overall survival in high-risk early stage breast cancer patients receiving cyclophosphamide-based therapy.” In Breast Cancer Research and Treatment, 100:S277–S277. SPRINGER, 2006.
       Link to Item
    • Potti, A., H. K. Dressman, A. H. Bild, J. R. Nevins, and P. K. Marcom. “Gene expression-based signatures of chemosensitivity and oncogenic pathway deregulation provide a novel approach to breast cancer therapeutics.” In Breast Cancer Research and Treatment, 100:S278–S278. SPRINGER, 2006.
       Link to Item
    • Underkoffler, D., G. Bean, J. Baker, V. Scott, L. Wilke, M. Troch, M. Dong, et al. “The frequency of loss of heterozygosity of RARb2 in random periareolar fine needle aspiration samples of women at high risk of developing breast cancer.” In Breast Cancer Research and Treatment, 100:S59–60. SPRINGER, 2006.
       Link to Item
    • Marcom, P. K., C. Isaacs, L. Harris, M. Bryant, A. Kommareddy, Y. Tao, G. Mann, and M. J. Ellis. “A phase II trial of letrozole and trastuzumab for ER and/or PgR and HER2 positive metastatic breast cancer: Final results.” In Journal of Clinical Oncology, 23:27S-27S. AMER SOC CLINICAL ONCOLOGY, 2005.
       Link to Item
    • Anders, C. K., S. A. Snyder, R. C. Barrier, W. Demark-Wahnefried, R. A. Welch, P. K. Marcom, H. S. Shaw, S. Y. Chui, and K. L. Blackwell. “Inhibin A and B as predictive markers for chemotherapy-induced premature ovarian failure (POF) among premenopausal women with early stage breast cancer (ESBC).” In Breast Cancer Research and Treatment, 94:S47–S47. SPRINGER, 2005.
       Link to Item
    • Rumble, M., J. D. Edinger, F. J. Keefe, L. S. Porter, and P. K. Marcom. “A pilot study examining the utility of the cognitive-behavioral model of insomnia in early stage breast cancer patients.” In Sleep, 28:A228–A228. OXFORD UNIV PRESS INC, 2005.
       Link to Item
    • Seo, P. H., G. R. Bean, J. C. Baker, J. V. Scott, K. Rasheed, L. D. Yee, M. M. Troch, et al. “Association of RAR beta 2, ER, BRCA and p16 promoter methylation with cytologic atypia in random periareolar fine needle aspiration (RPFNA) breast tissue of asymptomatic women at high risk for breast cancer.” In Breast Cancer Research and Treatment, 94:S172–S172. SPRINGER, 2005.
       Link to Item
    • Blackwell, K. L., E. H. Kaplan, S. X. Franco, P. K. Marcom, J. E. Maleski, M. J. Sorensen, and M. S. Berger. “A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer.” In Journal of Clinical Oncology, 22:196S-196S. AMER SOC CLINICAL ONCOLOGY, 2004.
       Link to Item
    • Ratliff, B. E., G. Bean, P. K. Marcom, J. V. Scott, L. Yee, B. F. Kimler, C. J. Fabian, C. M. Zalles, H. Shaw, and V. L. Seewaldt. “RARbeta P2 promoter methylation: Potential biomarker for use with breast Random Periareolar Fine Needle Aspiration in breast cancer risk assessment.” In Journal of Clinical Oncology, 22:100S-100S. AMER SOC CLINICAL ONCOLOGY, 2004.
       Link to Item
    • Blackwell, K. L., H. Dressman, J. Olson, E. Rosen, P. K. Marcom, V. Liotcheva, E. Jones, et al. “Molecular signatures that predict response to anthracycline-taxane based neoadjuvant chemotherapy.” In Breast Cancer Research and Treatment, 88:S22–S22. SPRINGER, 2004.
       Link to Item
    • Blackwell, K. L., E. H. Kaplan, S. X. Franco, P. K. Marcom, J. E. Maleski, N. L. Spector, M. T. Stocum, M. J. Sorensen, and M. S. Berger. “Determining molecular phenotypes of metastatic breast cancer that respond to the small molecule inhibitor of ErbB1 and ErbB2, lapatinib (GW572016).” In Breast Cancer Research and Treatment, 88:S30–S30. SPRINGER, 2004.
       Link to Item
    • Blackwell, Kimberly, Edward H. Kaplan, Sandra X. Franco, P Kelly Marcom, Janet Maleski, Mel Sorensen, and Mark S. Berger. “A phase II, open-label, multicenter study of lapatinib (GW572016) in patients with metastatic breast cancer that has progressed on trastuzumab-containing reimens.” In Annals of Oncology, 15:27–27. OXFORD UNIV PRESS, 2004.
       Link to Item
    • Pittman, J. L., C. L. Tebbit, E. P. Black, H. K. Dressman, E. S. Huang, J. A. Olson, J. R. Marks, et al. “Predictive models that combine multiple forms of genomic and clinical data to achieve personalized prediction of outcomes in breast cancer.” In Breast Cancer Research and Treatment, 88:S21–22. SPRINGER, 2004.
       Link to Item
    • Larned, Z. L., L. Daly, P. K. Marcom, T. L. Ortel, S. O’Shea, C. Greenberg, and K. Blackwell. “A phase I safety and feasibility trial of subcutaneous hirudin (lepirudin) alone and in combination with chemotherapy in metastatic breast cancer patients.” In Blood, 102:126B-126B. AMER SOC HEMATOLOGY, 2003.
       Link to Item
    • Marcom, P. K., R. E. Coleman, M. J. Ellis, H. Shaw, D. Delong, and T. R. DeGrado. “A comparison study of F-18-labeled choline versus F-18-labeled 2-deoxyglucose positron emission tomography for evaluation of advanced breast cancer.” In Breast Cancer Research and Treatment, 76:S150–S150. KLUWER ACADEMIC PUBL, 2002.
       Link to Item
    • Miller, K. D., H. S. Rugo, M. A. Cobleigh, P. K. Marcom, L. I. Chap, F. A. Holmes, L. Fehrenbacher, et al. “Phase III trial of capecitabine (Xeloda (R)) plus bevacizumab (Avastin (TM)) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane.” In Breast Cancer Research and Treatment, 76:S37–S37. KLUWER ACADEMIC PUBL, 2002.
       Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.